DC Administration Services Accepting Non-dealer Committee Membership Applications for 2023
DC Administration Services, Inc. (DCAS) would like to invite all interested Members of ISDA to apply for a position as a Non-dealer Committee Member of the Determinations Committee for the relevant region.
Parties wishing to apply for such a position should carefully review and submit an executed Non-dealer Committee Participation Letter by 5pm (New York time) on Thursday, March 16, 2023.
For more information on the process and to download the form of the Non-dealer Committee Participation Letter, please visit https://www.cdsdeterminationscommittees.org/about-dc-committees/constitution-of-the-determinations-committees/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005543/en/
Contact information
Inquires:
Orlando Figueroa
orlando.figueroa@citadelspv.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ookla Unveils Speedtest Pulse™, Redefining Network Validation and Troubleshooting10.11.2025 13:00:00 EET | Press release
Ookla®, a global leader in connectivity intelligence, today unveiled Speedtest Pulse™, a new network diagnostic device designed to provide definitive, smartphone-based validation and troubleshooting for internet service providers (ISPs) and enterprises. Leveraging the power of Speedtest®, a globally trusted gold standard for connectivity measurement, Speedtest Pulse bridges a crucial gap in technician toolkits, offering a powerful, scalable solution that is easy to use and provides clear, actionable insights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110605367/en/ Speedtest Pulse™ is a dual-mode network diagnostic tool offering one-tap, smartphone-based validation and troubleshooting, and autonomous testing of network performance and user experience. The launch comes at a pivotal inflection point for the industry. Wi-Fi is no longer a commodity; it is critical infrastructure for modern homes and businesses. It serves
Kaneka Expands Global Reach with i-ED COIL™ Launch in Europe10.11.2025 04:51:00 EET | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) has begun sales of its i-ED COIL™, a brain aneurysm embolization coil (*1), in Europe as of October. The product obtained EC certification (*2) under an EU Medical Device Regulation (*3) in July and will be distributed primarily in Europe through Kaneka Medical Europe N.V. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251109744229/en/ i-ED Coil The i-ED COIL™ provides world-class flexibility, enabled by its specialized wire thickness and structural features. This flexibility enables coils to be packed more densely within aneurysms than conventional products and allows treatment of aneurysms with irregular shapes. Its role in reducing the risk of aneurysm rupture is highly regarded by physicians, and since its launch in the Japanese market in 2019, sales have continued to grow steadily. Kaneka is expanding its business in a wide range
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week9.11.2025 00:15:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Results were presented today as a late-breaking oral presentation (SA-OR091) and included interim data from the open-label Phase 1/2 RUBY-3 trial, where adults with IgAN and pMN received pove subcutaneously every 4 weeks. The analysis included 21 participants with IgAN and 10 participants with pMN treated with pove at the 80mg dose, of which 17 participants and 5 participants, respectively, completed the Week 48 study visit. Results in IgAN In IgAN,
Westinghouse and Hungary Establish Landmark Nuclear Fuel Partnership8.11.2025 16:00:00 EET | Press release
Westinghouse Electric Company and MVM Group signed a contract to ensure diversification of fuel supply in Hungary. This partnership brings to Paks Nuclear Power Plant (NPP) reliable supply with Westinghouse VVER fuel, manufactured in Europe. The Westinghouse VVER-440 fuel reload deliveries will start in 2028, subject to licensing activities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107682814/en/ Westinghouse Nuclear Fuel Senior Vice President Aziz Dag, left, and Károly Mátrai, CEO of the MVM Group, signed the Paks VVER-440 contract, Nov. 7, 2025. “Our agreement with Westinghouse is a clear response to today's energy challenges and further strengthens the role of Hungary's leading base power plant in the domestic energy supply. This strategically important step will make the operation of Paks Nuclear Power Plant safer and more flexible. The diversified fuel procurement reduces external exposures and provides predicta
OMRON Releases the “Medium-Term Roadmap SF 2nd Stage”8.11.2025 08:00:00 EET | Press release
OMRON (TOKYO: 6645) has announced its “Medium-Term Roadmap Shaping the Future 2nd Stage (“SF 2nd Stage”),” covering from FY2026 to FY2030, on November 7, 2025 (JST). This Roadmap presents the Group’s vision and growth strategies through 2030, which are disclosed on our corporate website. Overview of the “Medium-Term Roadmap SF 2nd Stage” Since April 2024, OMRON has been implementing a Structural Reform Program “NEXT 2025” aimed at rebuilding our foundation for profitability and growth. With the completion of this Program in September 2025, we have shifted into a growth phase and formulated a new Roadmap looking ahead to 2030. This Roadmap identifies Business Portfolio Restructuring as a core strategy. We have defined Thirteen Focus Businesses to drive the Group’s future growth. By accelerating our selection and concentration efforts, we aim to build a “distinctive” business portfolio that maximizes overall Group growth. Furthermore, to maximize the growth potential of our Focus Busines
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom